Mirabegron
- Generic Name
- Mirabegron
- Brand Names
- Myrbetriq, Betmiga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24N4O2S
- CAS Number
- 223673-61-8
- Unique Ingredient Identifier
- MVR3JL3B2V
- Background
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
- Indication
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
- Conditions
- Interventions
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01964183
Specified Drug Use-results Survey of Betanis Tablets
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 300
- Registration Number
- NCT01898624
Beta 3 Agonist Treatment in Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Henning Bundgaard
- Target Recruit Count
- 70
- Registration Number
- NCT01876433
- Locations
- 🇦🇺
Monash Center of Cardiovascular Research., Melbourne, Australia
🇩🇰Department of Cardiology, The Heart Centre, Rigshospitalet Copenhagen University Hospital., Copenhagen Ø, Denmark
🇦🇺Department of Cardiology, Royal North Shore Hospital., Sydney, Australia
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 223
- Registration Number
- NCT01745094
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 1887
- Registration Number
- NCT01638000
- Locations
- 🇦🇲
Site: 37404, Yerevan, Armenia
🇦🇲Site: 37402, Yerevan, Armenia
🇦🇹Site: 43013, Linz, Austria
A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 32
- Registration Number
- NCT01579461
- Locations
- 🇸🇰
FNsP Bratislava, nemocnica akad. L. Dérera; Klinika pracovného lekárstva a toxikológie, Bratislava, Slovakia
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 48
- Registration Number
- NCT01489696
- Locations
- 🇬🇧
Covance CRU Ltd, Leeds, United Kingdom
To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 28
- Registration Number
- NCT01478490
- Locations
- 🇳🇱
PRA International (former Pharma Bio-Research), Zuidlaren, Netherlands
A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01478529
- Locations
- 🇳🇱
Pharma Bio Research, Zuidlaren, Netherlands
To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 28
- Registration Number
- NCT01478568
- Locations
- 🇫🇷
SGS Aster, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.